Universiteit Maastricht — Clinical Trial Site

44 Registered trials

15 Currently recruiting

Organisation

Universiteit Maastricht

Location

Maastricht, Netherlands

Identifier

ORG-100014334

Address

P. O. Box 616, 6200 MD, Netherlands

Departments

#2301
#40565:Vascular medicine
40565: Vascular medicine
anesthesiology
Cardiology
Department of Cardiology
Department of pulmonary diseases
EPZ MUMC+
gastroenterology
Hematology
Huisartsengeneeskunde
Huisartsgeneeskunde
Longziekten
Maastricht University Medical Center
Medical Oncology
Medische Oncologie
N/A
Neurology
Neuropsychology and Psychopharmacology
NL10010, Afdeling MDL
NP & PP
Nutrition and Movement Sciences
Obstetrie en Gynaecologie
Oncology
Psychiatry and Neuropsychology
Reproductive medicine and gynecology

Clinical trials at this site (44)

Search interface

Treatments of COVID-19 in primary care in the Netherlands Not authorised

2022-500678-33-00 Patients with COVID-19 in the community, referred by th 6
An early access study of ivosidenib in patients with a pretreated locally advanced or metastatic cholangiocarcinoma Not authorised

2022-501463-40-00 Locally Advanced or Metastatic Cholangiocarcinoma 5
SAFEST Not authorised

2022-502059-79-00 Ischemic stroke or transient ischemic attack 6
Microdosing for ADHD and emotion regulation Not authorised

2025-520906-36-00 Attention Deficit Hyperactivity Disorder (ADHD) 4
TMSxDCS: Medicinal improvement of brain stimulation for depression. Pending

2025-521166-95-00 Major Depressive Disorder (MDD) 4
A research study to see how NNC0487-0111 affects the body’s energy use after a weight loss in adults living with obesity, compared to a low-… Pending

2025-522744-40-00 Obesity 3
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting

2022-501007-28-00 Breast Neoplasms 5 2023-04-18
Phase 3 Trial of TAK-330 for Reversal of Direct Oral Factor Xa Inhibitor-induced Anticoagulation Recruiting

2022-503012-16-00 Patients on treatment with Factor Xa Inhibitor needing 5 2022-07-20
A trial to learn how safe the combination of rilvegostomig and chemotherapy is and how well it works compared to durvalumab and chemotherapy… Recruiting

2025-523085-24-00 Biliary Tract Cancer 5 2026-04-13
Role of BCAA in glucose homeostasis Recruiting

2023-503424-12-00 Type 2 diabetes 6 2025-04-14
A Phase 1/2 Study of VX-670 in Adult Subjects with Myotonic Dystrophy Type 1 Recruiting

2023-506028-10-00 Myotonic Dystrophy 7 2024-12-11
Stopping or continuing blood thinners after stroke at young age without a known cause: STOP trial Recruiting

2024-513092-40-00 Stroke 6 2024-12-05
A study to learn if dapirolizumab pegol works and is safe in people with moderately to severely active systemic lupus erythematosus (SLE) Recruiting

2023-508191-11-00 Systemic lupus erythematosus (SLE) 5 2024-11-28
A long-term follow-up study for patients treated with Galapagos CAR T cell therapies Recruiting

2023-510173-34-00 Relapsed/refractory multiple myeloma 5 2024-07-26
CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA Recruiting

2023-503317-29-00 Metastatic renal cell carcinoma (mRCC) 5 2024-04-12
A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participa… Recruiting

2023-503208-94-00 Prostate cancer 6 2024-04-04
Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-vol… Recruiting

2023-506698-36-00 low-volume metastatic castration-sensitive prostate can 5 2024-02-02
A phase 1/2a, open-label trial to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending doses o… Recruiting

2024-514328-18-00 Spinocerebellar ataxia types 1, 3 and Huntington's dise 7 2022-12-06
Pancreatitis and early omega-3-fatty acid infusion for reduction of organ failure and mortality. Recruiting

2023-505220-57-03 Predicted severe acute pancreatitis 5 2022-05-09
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten (CK-3773274) in Adults With Hypertrophic Cardiomyo… Recruiting

2023-508963-58-00 Symptomatic hypertrophic cardiomyopathy (HCM) 4 2022-01-31
GROINSS-V III Recruiting

2023-508722-99-00 Vulvar cancer 4 2020-11-19
Het effect van psilocybine op pijn bij fibromyalgiepatiënten: een multicenter trial Ended

2024-516890-63-00 Fibromyalgia 4 2025-01-21
A study to determine if ALXN2220 is effective, safe, and tolerable in adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Ended

2023-506669-70-00 Adults with Transthyretin Amyloid Cardiomyopathy (ATTR- 5 2024-04-30
A study of sigvotatug vedotin versus docetaxel in previously treated non-small cell lung cancer (Be6A Lung-01) Ended

2023-503827-25-01 Non-Small Cell Lung Cancer (NSCLC) 5 2024-02-16